~~<i id='165FC9F42F'><strike id='165FC9F42F'><tt id='165FC9F42F'><pre id='165FC9F42F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

author：entertainment 2025-09-02 17:43:52 - browse：75291

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： 'The View' co

hotspot

leisure time

knowledge

hotspot

entertainment

Violenceagainstdoctors,nurses,andotherhealth-careprovidersisontherise.FredDufour/AFP/GettyImagesViol

WSS

'The View' co

Plastic surgeons increase patient psychiatric screenings

'The View' co

Hey, doctors: Don't be no

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

explore

explore

hotspot

At least 13 dead in Texas as scorching temps continue

Positive childhood experiences can help future health

Sports medicine is finally prioritizing gender equality

New chief aims to remake Sanofi Genzyme

Supreme Court strikes down use of affirmative action

Colonoscopy prep: Liquid

Dobbs anniversary: the lost opportunity of abortion as health care

Intermittent fasting comes with a heart risk? Not so fast

Dobbs anniversary: the lost opportunity of abortion as health care

Biden White House, tech companies launch new safeguards around emerging AI technology

leisure time

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

What is artificial intelligence? Experts weigh in

Why Marc Tessier

'The View' co

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Why Marc Tessier

knowledge

hotspot

hotspot

entertainment